Comorbidity of psychopathological domains in community-dwelling persons with Alzheimer's disease

被引:21
|
作者
Tractenberg, RE
Weiner, MF
Patterson, MB
Teri, L
Thal, LJ
机构
[1] Georgetown Univ, Ctr Populat & Hlth, Washington, DC 20057 USA
[2] Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75230 USA
[3] Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75230 USA
[4] Univ Hosp Cleveland, Dept Psychiat, Cleveland, OH 44106 USA
[5] Univ Washington, Dept Psychosocial & Community Hlth, Seattle, WA 98195 USA
[6] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA
[7] Univ Washington, Dept Psychol, Seattle, WA 98195 USA
[8] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA
关键词
psychopathology; Alzheimer's; comorbidity; psychosis; agitation; depression;
D O I
10.1177/0891988703016002006
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
In this post hoc analysis of baseline responses to the CERAD Behavior Rating Scale for Dementia in a clinical trial of interventions for agitation in Alzheimer's disease (AD), the authors investigated the distribution of, and relationships between, agitation, depression, and psychosis in 148 individuals with AD. Prevalence of depressive symptoms was highest (78.4%), followed by agitation (77.6%) and psychotic symptoms (69.3%); 51.1% of the sample had symptoms in all 3 domains. Cross-sectionally, psychotic symptoms were most closely associated with Mini-Mental State Examination (MMSE) scores, while agitation was less so. Depressive symptoms were relatively consistently prevalent across MMSE levels. After controlling for the presence of agitated symptoms, psychosis and depression were significantly associated, but neither symptoms of psychosis nor of depression were associated with agitation when depression or psychosis, respectively, was controlled for. Significant psychopathological comorbidity should be considered in the design of clinical trials targeting particular psychopathology in this disease population.
引用
收藏
页码:94 / 99
页数:6
相关论文
共 50 条
  • [21] Long-Term Use of Opioids Among Community-Dwelling Persons with and without Alzheimer's Disease
    Hamina, Aleksi
    Taipale, Heidi
    Tanskanen, Antti
    Tolppanen, Anna-Maija
    Tiihonen, Jari
    Hartikainen, Sirpa
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 369 - 369
  • [22] Risk of Pneumonia Associated with Incident Benzodiazepine Use Among Community-Dwelling Persons with Alzheimer's Disease
    Taipale, Heidi
    Tolppanen, Anna-Maija
    Koponen, Marjaana
    Tanskanen, Antti
    Lavikainen, Piia
    Sund, Reijo
    Tiihonen, Jari
    Hartikainen, Sirpa
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 367 - 367
  • [23] Antidepressant use and risk of hip fractures among community-dwelling persons with and without Alzheimer's disease
    Torvinen-Kiiskinen, Sanna
    Tolppanen, Anna-Maija
    Koponen, Marjaana
    Tanskanen, Antti
    Tiihonen, Jari
    Hartikainen, Sirpa
    Taipale, Heidi
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2017, 32 (12) : E107 - E115
  • [24] Incidence and Duration of Cumulative Bisphosphonate Use among Community-Dwelling Persons with or without Alzheimer's Disease
    Tiihonen, Miia
    Taipale, Heidi
    Tanskanen, Antti
    Tiihonen, Jari
    Hartikainen, Sirpa
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 52 (01) : 127 - 132
  • [25] Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer's Disease
    Koponen, Marjaana
    Taipale, Heidi
    Lavikainen, Piia
    Tanskanen, Antti
    Tiihonen, Jari
    Tolppanen, Anna-Maija
    Ahonen, Riitta
    Hartikainen, Sirpa
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 56 (01) : 107 - 118
  • [26] Mean number of drugs and prevalence of polypharmacy among community-dwelling persons with and without Alzheimer's disease
    Taipale, Heidi
    Koponen, Marjaana
    Tolppanen, Anna-Maija
    Tiihonen, Jari
    Hartikainen, Sirpa
    Tanskanen, Antti
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 300 - 300
  • [27] Duration of new antidepressant use and factors associated with discontinuation among community-dwelling persons with Alzheimer's disease
    Kettunen, Reetta
    Taipale, Heidi
    Tolppanen, Anna-Maija
    Tanskanen, Antti
    Tiihonen, Jari
    Hartikainen, Sirpa
    Koponen, Marjaana
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (03) : 417 - 425
  • [28] Duration of new antidepressant use and factors associated with discontinuation among community-dwelling persons with Alzheimer’s disease
    Reetta Kettunen
    Heidi Taipale
    Anna-Maija Tolppanen
    Antti Tanskanen
    Jari Tiihonen
    Sirpa Hartikainen
    Marjaana Koponen
    European Journal of Clinical Pharmacology, 2019, 75 : 417 - 425
  • [29] Use of antidepressants among community-dwelling persons with Alzheimer's disease: a nationwide register-based study
    Laitinen, Marja-Liisa
    Lonnroos, Eija
    Bell, J. Simon
    Lavikainen, Piia
    Sulkava, Raimo
    Hartikainen, Sirpa
    INTERNATIONAL PSYCHOGERIATRICS, 2015, 27 (04) : 669 - 672
  • [30] Incident Use of a Potentially Inappropriate Medication and Hip Fracture in Community-Dwelling Older Persons With Alzheimer's Disease
    Hyttinen, Virva
    Taipale, Heidi
    Tolppanen, Anna-Maija
    Tanskanen, Antti
    Tiihonen, Jari
    Hartikainen, Sirpa
    Valtonen, Hannu
    ANNALS OF PHARMACOTHERAPY, 2017, 51 (09) : 725 - 734